Acumentis signs national agreement for Swab First’s drug screening technology

Acumentis is excited to announce the signing of a national agreement with Swab First to partner the delivery of its revolutionary drug screening technology into the residential and commercial property sector.

The drug screening technology developed and commercialised by Swab First is specifically focused on identifying contamination from drug residue in residential and commercial buildings. This emerging global issue is caused by the reckless manufacture, trafficking and use of illicit substances. Residue from this activity is responsible for an array of mental and respiratory health issues. Homeowners, agents are landlords are exposed to commercial risk through unlawful amendments to property, cost of remediation and clean up, along with a duty of care to staff and tenants.

Swab First have developed a sample collection and analysis process using border security equipment. The solution developed by experienced exposure health scientists is of high integrity and an accuracy in line with international standards. The reports provide information that assists clients to make important decisions relating to their exposure to the health and commercial risks of having a property contaminated with drug residue. Swab First’s place in the market is alongside all other condition assessments done at a similar price point, like pest and building inspections at the point of sale or tenancy inspection.

The partnership will see Acumentis add the Swab First Premium Property Screen products to their suite of offerings, primarily for property and banking sectors. The team at Acumentis are authorised and trained sample collectors, with swabs taken during routine valuations and a report provided within 48 hours confirming if any harmful drug residue is present..

This service will benefit;

  • Real estate agents, investors, relocation agents and large companies wanting to ensure duty of care for employees and tenants.
  • Prospective home buyers or renters, to provide confidence the property is safe for occupancy.
  • Liquidators and administrators wanting to confirm property health and any potential remediation required.

The Acumentis and Swab First partnership establishes a national footprint for Swab First’s drug screening technology. The service is available immediately to metropolitan and regional clients in WA, SA, QLD, NSW and VIC.

For further information and sales contacts, please contact the following:

Leigh Whicker
Chief Executive Officer Swab First Pty Ltd
Email: leigh.whicker@swabfirst.com.au
Phone: 0431 605 501

Nathan King
AAPI National Director – Advisory, State Government & Projects
Certified Practising Valuer Acumentis Pty Ltd
Email: Nathan.king@acumentis.com.au
Phone: 0416 082 499

Want to hear more
from Acumentis?

Sign up to our mailing list

  • This field is for validation purposes and should be left unchanged.